GlassScriptPhysician profile
Eric J Houchin
NPI 1174522957
$59,181.92
in general payments reported to CMS, 2019-2025
22 companies · $7,415 in 2025
The $7,415 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $7,996 · 2021: $605 · 2022: $11K · 2023: $10K · 2024: $10K · 2025: $7,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $1,984 · Consulting Fee: $900 · Travel and Lodging: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,740.00 |
| Food and Beverage | $1,984.29 |
| Consulting Fee | $900.00 |
| Travel and Lodging | $568.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $37,960.40 | 2019-2025 | Vivitrol, Vivitrol |
| Indivior INC. | $18,422.34 | 2019-2022 | |
| Novo Nordisk INC | $2,083.73 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Braeburn INC. | $254.94 | 2025 | Brixadi |
| Astrazeneca Pharmaceuticals LP | $105.66 | 2019-2024 | Flumist Quadrivalent, Farxiga |
| Glaxosmithkline, LLC. | $54.64 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $42.93 | 2023-2024 | |
| Dexcom, INC. | $25.80 | 2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $24.68 | 2019 | |
| Csl Behring | $21.63 | 2024 | Kcentra |
| Bioventus LLC | $18.51 | 2021 | |
| Astellas Pharma US INC | $18.23 | 2019 | |
| Merck Sharp & Dohme LLC | $18.06 | 2024 | Vaxneuvance, Capvaxive, Gardasil |
| Orexo US, INC. | $16.66 | 2019 | |
| Sanofi Pasteur INC. | $16.44 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $15.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.05 | 2019 | |
| Amgen INC. | $14.77 | 2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $13.79 | 2019 | |
| Pfizer INC. | $13.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Houchin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.